However, as a new type of “living drug”, CD19 CAR-T cells can cause various degrees of cytokine release syndrome (12), immune effector cell-associated neurotoxicity syndrome (ICANS), and various forms of special B-cell deficiency, such as infection and low toxicity (Figure 1) (13–15). Here, CD19 is linked to B cell deficiency.